Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 12/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 12/20 | 0.36 |
| ▸ | KDR | P35968 | 6/20 | 0.34 |
| ▸ | ERBB3 | P21860 | 3/20 | 0.34 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.34 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.32 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2749135 | 0.80 | FGFR1 (0.40) | FGFR1FGFR4EGFRERBB2KDR | |
| SCHEMBL2749873 | 0.79 | EGFR (0.56) | FGFR1FGFR4EGFRERBB2ERBB3 | |
| SCHEMBL3403862 | 0.79 | FGFR1 (0.40) | FGFR1FGFR4EGFRERBB2KDR | |
| SCHEMBL3506358 | 0.78 | FGFR1 (0.39) | FGFR1FGFR4EGFRERBB2KDR | |
| SCHEMBL2748776 | 0.77 | FGFR1 (0.40) | FGFR1FGFR4EGFRERBB2ERBB3 | |
| SCHEMBL2749352 | 0.77 | EGFR (0.44) | FGFR1FGFR4EGFRERBB2KDR | |
| SCHEMBL2748523 | 0.77 | FGFR1 (0.42) | FGFR1FGFR4EGFRERBB2KDR | |
| SCHEMBL27684259 | 0.77 | FGFR1 (0.42) | FGFR1FGFR4EGFRERBB2ERBB3 | |
| SCHEMBL2747761 | 0.77 | FGFR1 (0.41) | FGFR1FGFR4KDR | |
| SCHEMBL3829641 | 0.77 | FGFR1 (0.44) | FGFR1FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2253633-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | disclosed |
| US-20090233937-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233937-A1 | FUSED HETEROCYCLIC COMPOUND | ROS1, JAK2, ERBB2 | FGFR1 9/4885FGFR4 54/4885EGFR 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.